Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation Treatment With Combination Pyrimidine Nucleosides in TK2 Deficiency
NCT03845712Phase 2Completed
- Sponsor
- UCB
- Start
- Jul 2019
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
A Phase 2 trial of 2'-deoxycytidine, doxribtimine in thymidine kinase 2 deficiency (TK2D), sponsored by UCB. Started Jul 2019; status: completed.
02
Drugs
2'-deoxycytidinedoxribtimine
03
Conditions
thymidine kinase 2 deficiency (TK2D)
Beyond the preview
Go deeper on NCT03845712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845712.